ADVFN - Advanced Financial Network.
HOME» NYSE » M » MRK Stock Price » MRK Stock News

Merck Share News

 Merck & Co., Stock Price
MRK Stock Price
 Merck & Co., Stock Chart
MRK Stock Chart
 Merck & Co., Stock News
MRK Stock News
 Merck & Co., Company Information
MRK Company Information
 Merck & Co., Stock Trades
MRK Stock Trades

Cardiome To Slash Workforce by 85% on End of Merck's Oral Development Program

By Chelsea Stevenson Cardiome Pharma Corp. (CRME) plans to reduce its workforce by about 85% in response to the termination of Merck & Co.'s (MRK) developing vernakalant oral program. All positions focused on internal research and certain supporting functions will be eliminated, Canadian-based Cardiome Pharma said. The reductions will result in up to $5 million in severance charges over the remainder of the year. In March, Cardiome's partner Merck discontinued its development of its oral vernakalant drug, which prevented atrial fibrillation. Cardiome had said it was disappointed with Merck's decision. Interim Chief Executive Dr. William Hunter said the board regrets the effects of the decision. Dr. Hunter replaced former Chief Executive Doug Janzen, who left the company last week. Cardiome Pharma reported a slightly narrower loss for its first quarter, citing clinical development efforts and pre-clinical research project expenditures. The latest quarter's loss also includes employee termination charges. The company said it will issue a further progress report in mid-August to its shareholders. Shares were off 2.3% to 43 cents in recent trading and have dropped 84% this year. Write to Chelsea Stevenson at

Stock News for Merck (MRK)
10/24/201621:40:00Merck Drug Gets FDA Approval as a First-Line Lung Cancer Treatment
10/24/201620:50:00Merck Drug Gets FDA Approval as a First-Line Lung Cancer Treatment
10/24/201618:04:00FDA Approves Merck’s KEYTRUDA® (pembrolizumab) in Metastatic NS...
10/21/201621:57:00FDA Approves Merck’s ZINPLAVA™ (bezlotoxumab) to Reduce Recurrence of...
10/21/201606:45:00Merck’s KEYNOTE-045 Studying KEYTRUDA® (pembrolizumab) in Ad...
10/19/201607:00:00Merck Announces Pivotal Phase 3 Study of Letermovir, an Investigational...
10/17/201617:00:00Merck Research Laboratories Facilities Designated as “Milestones i...
10/14/201608:30:00Merck Launches Biosimilars Clarified, a New Online Educational...
10/10/201602:49:00Merck Announces Recipients of Third Annual €1 Million 'Grant f...
10/09/201602:44:00Study May Boost Use of Merck Lung-Cancer Drug
10/09/201602:16:00Two Major Studies to Be Presented at ESMO 2016 Congress Presidential...
10/09/201602:15:00KEYTRUDA® (pembrolizumab) Showed Continued Overall Survival...
10/08/201608:45:00Merck Announces Longer-Term Follow-Up of Overall Survival Data...
10/08/201602:15:00New KEYTRUDA® (pembrolizumab) Data in Advanced Urothelial Cancer...
10/07/201616:05:00Merck Animal Health Announces USDA Approval of Innovative Canine...
10/04/201618:03:00FDA Warns on Hepatitis C Drugs
10/04/201617:14:53Statement of Changes in Beneficial Ownership (4)
10/04/201617:14:53Statement of Changes in Beneficial Ownership (4)
10/04/201617:14:53Statement of Changes in Beneficial Ownership (4)
10/04/201617:14:26Statement of Changes in Beneficial Ownership (4)

Merck and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2016 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations